Details of the Drug

General Information of Drug (ID: DMFJTDI)

Drug Name
Sibutramine
Synonyms
Butramin; Medaria; Meridia; Reductil; Sibutramina; Sibutraminum; Sibutramina [Spanish]; Sibutraminum [Latin]; BTS-54524; Butramin (TN); Ectiva (TN); Meridia (TN); Reductil (TN); Sibutramine (INN); Sibutramine [INN:BAN]; N-1-(1-(4-chlorophenyl)cyclobutyl)-3-methylbutyl-N,N-dimethylamine HCl; 1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Approved [1]
Therapeutic Class
Appetite Depressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 279.8
Logarithm of the Partition Coefficient (xlogp) 5.4
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance
The apparent oral clearance of drug is 1750 L/h []
Elimination
0% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.1 hours [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7657 micromolar/kg/day [4]
Water Solubility
The ability of drug to dissolve in water is measured as 2.9 mg/mL [2]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Lose weight rs5443 GNB3 OTA6HYBA [5]
Chemical Identifiers
Formula
C17H26ClN
IUPAC Name
1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
Canonical SMILES
CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
InChI
InChI=1S/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3
InChIKey
UNAANXDKBXWMLN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5210
ChEBI ID
CHEBI:9137
CAS Number
106650-56-0
DrugBank ID
DB01105
TTD ID
D08KVZ
VARIDT ID
DR00566
INTEDE ID
DR1479
ACDINA ID
D00400
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Modulator [6]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Modulator [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [8]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [8]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [8]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Gene/Protein Processing [9]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [9]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [9]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Gene/Protein Processing [8]
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 (GNB3) OTA6HYBA GBB3_HUMAN Drug Response [5]
Proteasome subunit beta type-5 (PSMB5) OTOZXAS6 PSB5_HUMAN Gene/Protein Processing [8]
Proteasome subunit beta type-8 (PSMB8) OTW5XGMF PSB8_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Obesity
ICD Disease Classification 5B81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sibutramine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Sibutramine and Lorcaserin. Obesity [5B80-5B81] [10]
Propylhexedrine DMTBW2O Moderate Additive hypertensive effects by the combination of Sibutramine and Propylhexedrine. Obesity [5B80-5B81] [11]
Coadministration of a Drug Treating the Disease Different from Sibutramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Sibutramine and Methylene blue. Acquired methaemoglobinaemia [3A93] [12]
Oliceridine DM6MDCF Moderate Additive serotonergic effects by the combination of Sibutramine and Oliceridine. Acute pain [MG31] [13]
Inotersen DMJ93CT Moderate Increased risk of bleeding by the combination of Sibutramine and Inotersen. Amyloidosis [5D00] [14]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Sibutramine and Cilostazol. Arterial occlusive disease [BD40] [14]
Levalbuterol DM5YBO1 Moderate Additive hypertensive effects by the combination of Sibutramine and Levalbuterol. Asthma [CA23] [11]
Pirbuterol DMI5678 Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Pirbuterol. Asthma [CA23] [11]
Ephedrine DMMV0KW Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Ephedrine. Asthma [CA23] [11]
Desipramine DMT2FDC Major Additive serotonergic effects by the combination of Sibutramine and Desipramine. Attention deficit hyperactivity disorder [6A05] [15]
Dalfopristin DM4LTKV Minor Decreased metabolism of Sibutramine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Clarithromycin DM4M1SG Minor Decreased metabolism of Sibutramine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [16]
Troleandomycin DMUZNIG Minor Decreased metabolism of Sibutramine caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [11]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Sibutramine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [17]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Sibutramine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
Tucatinib DMBESUA Minor Decreased metabolism of Sibutramine caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [11]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Sibutramine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [19]
Olodaterol DM62B78 Moderate Additive hypertensive effects by the combination of Sibutramine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [16]
Vilanterol DMF5EK1 Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [11]
Indacaterol DMQJHR7 Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [16]
Arformoterol DMYM974 Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [16]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Sibutramine and Dihydrocodeine. Chronic pain [MG30] [20]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Sibutramine and Levomilnacipran. Chronic pain [MG30] [15]
Anisindione DM2C48U Moderate Increased risk of bleeding by the combination of Sibutramine and Anisindione. Coagulation defect [3B10] [19]
Regorafenib DMHSY1I Moderate Increased risk of bleeding by the combination of Sibutramine and Regorafenib. Colorectal cancer [2B91] [14]
Ardeparin DMYRX8B Moderate Increased risk of bleeding by the combination of Sibutramine and Ardeparin. Coronary thrombosis [BA43] [14]
Osilodrostat DMIJC9X Minor Decreased metabolism of Sibutramine caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [11]
MK-8228 DMOB58Q Minor Decreased metabolism of Sibutramine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [16]
Danaparoid DM6CLBN Moderate Increased risk of bleeding by the combination of Sibutramine and Danaparoid. Deep vein thrombosis [BD71] [21]
Rivaroxaban DMQMBZ1 Moderate Increased risk of bleeding by the combination of Sibutramine and Rivaroxaban. Deep vein thrombosis [BD71] [14]
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Sibutramine and Vilazodone. Depression [6A70-6A7Z] [15]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Sibutramine and Vortioxetine. Depression [6A70-6A7Z] [15]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Sibutramine and Isocarboxazid. Depression [6A70-6A7Z] [22]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Sibutramine and Milnacipran. Depression [6A70-6A7Z] [15]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Sibutramine and Escitalopram. Depression [6A70-6A7Z] [15]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Sibutramine and Desvenlafaxine. Depression [6A70-6A7Z] [15]
Clomipramine DMINRKW Major Additive serotonergic effects by the combination of Sibutramine and Clomipramine. Depression [6A70-6A7Z] [15]
Doxepin DMPI98T Major Additive serotonergic effects by the combination of Sibutramine and Doxepin. Depression [6A70-6A7Z] [15]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Sibutramine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [10]
LEVONORDEFRIN DMWDJ0H Moderate Increased risk of rapid heart rate by the combination of Sibutramine and LEVONORDEFRIN. Discovery agent [N.A.] [11]
Stiripentol DMMSDOY Moderate Decreased metabolism of Sibutramine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [23]
Mephentermine DMFJH5Q Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Mephentermine. Essential hypertension [BA00] [11]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Sibutramine and Tazemetostat. Follicular lymphoma [2A80] [19]
Itraconazole DMCR1MV Minor Decreased metabolism of Sibutramine caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [16]
Miconazole DMPMYE8 Minor Decreased metabolism of Sibutramine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [16]
Avapritinib DMK2GZX Moderate Increased risk of bleeding by the combination of Sibutramine and Avapritinib. Gastrointestinal stromal tumour [2B5B] [19]
Dichlorphenamide DMH7IDQ Moderate Increased risk of hyponatremia by the combination of Sibutramine and Dichlorphenamide. Glaucoma [9C61] [24]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Sibutramine and Sulfinpyrazone. Gout [FA25] [19]
Tetrahydrozoline DMT57WC Moderate Additive hypertensive effects by the combination of Sibutramine and Tetrahydrozoline. Herpes simplex infection [1F00] [11]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Sibutramine and Procarbazine. Hodgkin lymphoma [2B30] [22]
Saquinavir DMG814N Minor Decreased metabolism of Sibutramine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [16]
Etravirine DMGV8QU Moderate Increased metabolism of Sibutramine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Darunavir DMN3GCH Minor Decreased metabolism of Sibutramine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [16]
Berotralstat DMWA2DZ Minor Decreased metabolism of Sibutramine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [11]
Naphazoline DMJFZDL Moderate Additive hypertensive effects by the combination of Sibutramine and Naphazoline. Itching [1F28-1G07] [11]
Ceritinib DMB920Z Minor Decreased metabolism of Sibutramine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [16]
PF-06463922 DMKM7EW Moderate Increased metabolism of Sibutramine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [26]
Selpercatinib DMZR15V Minor Decreased metabolism of Sibutramine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [11]
Idelalisib DM602WT Minor Decreased metabolism of Sibutramine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [16]
IPI-145 DMWA24P Minor Decreased metabolism of Sibutramine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
Acalabrutinib DM7GCVW Moderate Increased risk of bleeding by the combination of Sibutramine and Acalabrutinib. Mature B-cell lymphoma [2A85] [14]
Ibrutinib DMHZCPO Moderate Increased risk of bleeding by the combination of Sibutramine and Ibrutinib. Mature B-cell lymphoma [2A85] [14]
Ponatinib DMYGJQO Moderate Increased risk of bleeding by the combination of Sibutramine and Ponatinib. Mature B-cell lymphoma [2A85] [14]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Sibutramine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [27]
Danazol DML8KTN Minor Decreased metabolism of Sibutramine caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [16]
Lasmiditan DMXLVDT Major Additive serotonergic effects by the combination of Sibutramine and Lasmiditan. Migraine [8A80] [15]
Exjade DMHPRWG Moderate Increased risk of bleeding by the combination of Sibutramine and Exjade. Mineral absorption/transport disorder [5C64] [14]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Sibutramine and Flibanserin. Mood disorder [6A60-6E23] [28]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Sibutramine and Ozanimod. Multiple sclerosis [8A40] [22]
Fedratinib DM4ZBK6 Moderate Increased risk of bleeding by the combination of Sibutramine and Fedratinib. Myeloproliferative neoplasm [2A20] [16]
Nilotinib DM7HXWT Moderate Decreased metabolism of Sibutramine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Sibutramine and Ruxolitinib. Myeloproliferative neoplasm [2A20] [14]
Dasatinib DMJV2EK Moderate Increased risk of bleeding by the combination of Sibutramine and Dasatinib. Myeloproliferative neoplasm [2A20] [14]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Sibutramine and Prasugrel. Myocardial infarction [BA41-BA43] [14]
Vorapaxar DMA16BR Moderate Increased risk of bleeding by the combination of Sibutramine and Vorapaxar. Myocardial infarction [BA41-BA43] [14]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Sibutramine and Bupropion. Nicotine use disorder [6C4A] [30]
Entrectinib DMMPTLH Minor Decreased metabolism of Sibutramine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [11]
Polythiazide DMCH80F Moderate Increased risk of hyponatremia by the combination of Sibutramine and Polythiazide. Oedema [MG29] [24]
Urea DMUK75B Moderate Increased risk of hyponatremia by the combination of Sibutramine and Urea. Oesophagitis [DA24] [24]
Levomethadyl Acetate DM06HG5 Moderate Additive CNS depression effects by the combination of Sibutramine and Levomethadyl Acetate. Opioid use disorder [6C43] [13]
Rucaparib DM9PVX8 Minor Decreased metabolism of Sibutramine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [16]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Sibutramine and Oxymorphone. Pain [MG30-MG3Z] [13]
Dezocine DMJDB0Y Moderate Additive serotonergic effects by the combination of Sibutramine and Dezocine. Pain [MG30-MG3Z] [13]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Sibutramine and Safinamide. Parkinsonism [8A00] [22]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Sibutramine and Rasagiline. Parkinsonism [8A00] [22]
Abametapir DM2RX0I Moderate Decreased metabolism of Sibutramine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [31]
Lefamulin DME6G97 Moderate Decreased metabolism of Sibutramine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [32]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Sibutramine and Choline salicylate. Postoperative inflammation [1A00-CA43] [19]
Lonafarnib DMGM2Z6 Minor Decreased metabolism of Sibutramine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [11]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Sibutramine and Epoprostenol. Pulmonary hypertension [BB01] [14]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Sibutramine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [33]
Voxelotor DMCS6M5 Minor Decreased metabolism of Sibutramine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [11]
Larotrectinib DM26CQR Minor Decreased metabolism of Sibutramine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [11]
LEE011 DMMX75K Minor Decreased metabolism of Sibutramine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Plicamycin DM7C8YV Moderate Increased risk of bleeding by the combination of Sibutramine and Plicamycin. Testicular cancer [2C80] [19]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Sibutramine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [34]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Sibutramine and Caplacizumab. Thrombocytopenia [3B64] [14]
Apixaban DM89JLN Moderate Increased risk of bleeding by the combination of Sibutramine and Apixaban. Thrombosis [DB61-GB90] [14]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Sibutramine and Cangrelor. Thrombosis [DB61-GB90] [19]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Sibutramine and Brilinta. Thrombosis [DB61-GB90] [14]
Cabozantinib DMIYDT4 Moderate Increased risk of bleeding by the combination of Sibutramine and Cabozantinib. Thyroid cancer [2D10] [14]
Xylometazoline DMKV32D Moderate Increased risk of rapid heart rate by the combination of Sibutramine and Xylometazoline. Vasomotor/allergic rhinitis [CA08] [11]
Betrixaban DM2C4RF Moderate Increased risk of bleeding by the combination of Sibutramine and Betrixaban. Venous thromboembolism [BD72] [19]
⏷ Show the Full List of 101 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sibutramine 5 mg capsule 5 mg Oral Capsule Oral
Sibutramine 10 mg capsule 10 mg Oral Capsule Oral
Sibutramine 15 mg capsule 15 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2586).
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene. Pharmacogenet Genomics. 2009 Sep;19(9):730-3. doi: 10.1097/FPC.0b013e3283307cf1.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999 Sep;33(9):968-78.
8 Sibutramine provokes apoptosis of aortic endothelial cells through altered production of reactive oxygen and nitrogen species. Toxicol Appl Pharmacol. 2017 Jan 1;314:1-11. doi: 10.1016/j.taap.2016.11.003. Epub 2016 Nov 9.
9 Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes. Chem Biol Interact. 2013 Sep 5;205(1):11-9.
10 Giese SY, Neborsky R "Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl." Plast Reconstr Surg 107 (2001): 293-4. [PMID: 11176649]
11 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
12 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
13 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
14 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
15 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
16 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
17 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
18 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
19 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
20 Das PK, Warkentin DI, Hewko R, Forrest DL "Serotonin syndrome after concomitant treatment with linezolid and meperidine." Clin Infect Dis 46 (2008): 264-5. [PMID: 18171260]
21 Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8. [PMID: 8826562]
22 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
23 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
24 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
25 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
26 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
28 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
29 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
30 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
31 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
32 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
33 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
34 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.